Global Antisense Oligonucleotide Therapeutics Market (2020 to 2030) – by Target Indication, Type of Therapy, Type of Molecule Type of Generation and Key Geographies – ResearchAndMarkets.com

Global Antisense Oligonucleotide Therapeutics Market (2020 to 2030) – by Target Indication, Type of Therapy, Type of Molecule Type of Generation and Key Geographies – ResearchAndMarkets.com




Global Antisense Oligonucleotide Therapeutics Market (2020 to 2030) – by Target Indication, Type of Therapy, Type of Molecule Type of Generation and Key Geographies – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Antisense Oligonucleotide Therapeutics Market by Target Indication, Type of Therapy, Type of Molecule Type of Generation and Key Geographies: Industry Trends and Global Forecasts, 2020-2030” report has been added to ResearchAndMarkets.com’s offering.

Since the approval of Vitravene in 1998, antisense oligonucleotide (ASO) therapies have evolved into a prominent class of therapeutics. In addition to the seven drugs, based on such molecules, that are commercially available, around 160 candidates are under development. Examples of recently approved antisense therapeutics include Viltepso, Vyondys 53 and Waylivra.

Given their ability to target the root cause of diseases, at the protein expression level, these disease-modifying interventions have potential applications across a wide range of therapeutic areas (including but not limited to oncological disorders, neurodegenerative disorders, respiratory disorders, and even certain rare genetic disorders). Further, recent advances in antisense oligonucleotide chemistry have enabled the development and synthesis of specialized oligonucleotides, having improved safety profiles and better cell targeting capabilities. In fact, these advanced variants of antisense oligonucleotide-based therapeutic candidates are deemed to possess the potential to cater to the unmet need for effective treatment options for diseases that were previously considered difficult to treat.

Presently, several drug developers, along with ASO technology providers, are actively engaged in the development of various antisense therapy candidates. Innovation in this field of research is mostly focused on improving cell targeting ability, target affinity, nuclease resistance, and optimizing toxicity profiles of antisense oligonucleotide candidates. Several big pharma players have also demonstrated interest in antisense oligonucleotide therapeutics and are investing both time and capital in this domain. The market has witnessed substantial partnership activity over the last few years. The activity in this segment of the industry has also attracted the attention of both private and public sector investors/investment funds, which have extended financial support to the initiatives of capable developer companies. Driven by encouraging clinical trial results, the antisense oligonucleotide therapies market is poised to witness healthy growth as multiple late stage drug candidates are approved and marketed over the coming decade.

Companies Mentioned

  • Abbott
  • AcedrA BioPharmaceutical
  • ACGT
  • Achieve Life Sciences
  • Agilent Technologies
  • Ajinomoto Bio-Pharma Services
  • Akcea Therapeutics
  • Alcyone Lifesciences
  • A Biotechnology & Pharmaceuticals
  • Allianz BioInnovation
  • Alta Bioscience
  • AM Chemicals
  • AmpTec
  • Amylon Therapeutics
  • Antisense Therapeutics
  • Applied Biological Materials
  • Aro Biotherapeutics
  • And Many More Companies!

In addition to other elements, the study includes:

  • A detailed assessment of the current market landscape of antisense oligonucleotide therapeutics, providing information on type of antisense molecule (RNA molecule and DNA molecule), ASO generation (first-generation, second-generation, third-generation and next-generation), phase of development (commercial, clinical, preclinical, and discovery stage) of lead candidates, target genes, target disease indications, target therapeutic areas, route of administration (subcutaneous, intravenous, intrathecal, intravitreal and others) and type of therapy (monotherapy, combination therapy and both). In addition, it provides details on drug developer(s), including year of establishment, company size, and location of headquarters.
  • Tabulated profiles of prominent antisense oligonucleotide therapeutic developers. Each profile features a brief overview of the company, its financial information (if available), product portfolio, recent developments and an informed future outlook.
  • An in-depth analysis of completed, ongoing and planned clinical studies of various antisense oligonucleotide therapeutics, based on the various relevant parameters, such as trial registration year, trial phase, trial recruitment status, enrolled patient population, study design, leading industry sponsors/collaborators (in terms of number of trials conducted), trial focus, target therapeutic area and target genes, highlighting popular indications, popular interventions and regional distribution of trials.
  • A detailed analysis of grants that have been awarded to research institutes for antisense oligonucleotide therapeutic projects, in the period between 2017 and 2020 (till September), on the basis of important parameters, such as year of grant award, amount awarded, administering institute center, support period, type of grant application, purpose of grant award, activity code, study section involved, type of recipient organizations and focus area. In addition, it highlights geographical distribution of recipient organizations, popular therapeutic areas, popular funding institute centers, prominent program officers, and popular recipient organizations.
  • An analysis of the partnerships that have been established in the recent past (2016-2020), covering acquisitions and mergers, licensing agreements, product development agreements, research agreements, joint venture agreements and other relevant types of deals.

Key Questions Answered

  • Who are the leading industry and non-industry players in this market?
  • What are the key therapeutic areas for which antisense oligonucleotide therapeutics are being/have been developed?
  • What are the prevalent trends within competitive landscape of antisense oligonucleotide therapeutics?
  • Which geographies are the most active in conducting clinical trials on antisense oligonucleotide therapeutics?
  • What kind of partnership models are commonly adopted by industry stakeholders?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Key Topics Covered:

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. ANTISENSE OLIGONUCLEOTIDE THERAPEUTICS: MARKET LANDSCAPE

5. COMPANY PROFILES

5.1. Chapter Overview

5.2. Antisense Therapeutics

5.3. Biogen

5.4. Bio-Path Holdings

5.5. Ionis Pharmaceuticals

5.6. ProQR Therapeutics

5.7. Sarepta Therapeutics

5.8. Sterna Biologicals

5.9. Wave Life Sciences

6. CLINICAL TRIAL ANALYSIS

7. ACADEMIC GRANTS ANALYSIS

8. PARTNERSHIPS AND COLLABORATIONS

9. MARKET FORECAST AND OPPORTUNITY ANALYSIS

10. CASE STUDY: OLIGONUCLEOTIDE MANUFACTURERS AND PURIFICATION SERVICES

11. CONCLUDING REMARKS

12. APPENDIX 1: TABULATED DATA

13. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

For more information about this report visit https://www.researchandmarkets.com/r/6nxhwa

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900